Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Generic Dabigatran Etexilate vs Pradaxa in Healthy Thai Volunteers
NCT06441916Phase 1Not yet recruiting
- Sponsor
- International Bio Service
- Start
- Sep 2024
- Primary completion
- Oct 2024
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of dabigatran in venous thromboembolism (VTE) and Atrial fibrillation (AFib) (2 arms), sponsored by International Bio Service. Primary endpoints: Peak Plasma Concentration, Area Under the Curve 0-48h and 1 more. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
dabigatran
03
Conditions
venous thromboembolism (VTE)Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT06441916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06441916.